-
Aubagio, Tecfidera are Comparable in Relapsing MS, Phase 4 Trial Finds
The effectiveness of Aubagio has been found to be superior to Tecfidera on whole brain atrophy in relapsing MS patients, yet similar for other MRI and clinical goals. Learn more about these findings here.
What do you think of this trial and its findings?
Sorry, there were no replies found.
Log in to reply.